Table 5.
Multivariate Logistic Regression Analysis for ISR frequency per injections.
| Variable | ISR frequency per patients | |
|---|---|---|
| Odd Ratio (95%CI) | P value | |
| Frequency of ISR | ||
| Fosaprepitant injection (Yes vs. No) | 4.565 (1.750- 11.908) | 0.0019 |
| Age (< 50 vs. ≥ 50) | 1.615 (0.525- 4.970) | 0.4031 |
| Chemotherapy regimen (AC vs (R-)CHOP) | 2.810 (0.799- 9.882) | 0.1073 |
| Chemotherapy regimen (AC vs FEC) | 3.401 (0.951-12.169) | 0.0598 |
| Body mass index (<22 vs. ≥ 22) | 2.235 (0.729- 6.854) | 0.1594 |
| Frequency of treatment-required ISR | ||
| Fosaprepitant injection (Yes vs. No) | 33.197 (4.113-267.916) | 0.0010 |
| Age (< 50 vs. ≥ 50) | 0.934 (0.231- 3.776) | 0.9234 |
| Chemotherapy regimen (AC vs (R-)CHOP) | 2.882 (0.645- 12.884) | 0.1660 |
| Chemotherapy regimen (AC vs FEC) | 1.556 (0.289- 8.381) | 0.6065 |
| Body mass index (<22 vs. ≥ 22) | 1.410 (0.350- 5.687) | 0.6289 |
CI, confidence intervals; ISR, injection site reaction; AC, doxorubicin/cyclophosphamide;
(R-)CHOP, rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone;
and FEC, 5-fluorouracil/epirubicin/cyclophosphamide.